URL has been copied successfully!
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
This newsletter was composed from a pediatric emergency department. Hot tip, all: Don’t jump off 6-foot playground equipment. You will scare your mother, and wind up in a cast.
The need-to-know this morning
- Kodiak Sciences said Zenkuda, its experimental vision-sparing treatment for a common cause of age-related blindness, achieved statistical equivalence to Eylea, a standard therapy, in a Phase 3 clinical trial.
- Merck said it paid $400 million upfront to China’s SciBrunch Therapeutics, for global license rights to a preclinical cancer drug that targets tumors with KRAS G12D mutations. The deal is valued at $2.13 billion if all future milestones are achieved.
Novo turns GLP-1 drugs into consumer products
Novo Nordisk is increasingly marketing its GLP-1 drugs less as treatments for a chronic disease and more as consumer products for people who simply want to lose weight, STAT’s Elaine Chen writes. It’s a shift that comes as insurance coverage for these obesity medicines remains limited.
Please follow us:
